Research progress on dendritic cell vaccines in cancer immunotherapy
/in Dendritic Cells, International Publications /von 2022-01-24 / Exp Hematol Oncol 2022 Jan;11(1):3Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma
/in Dendritic Cells, Glioblastoma, Immunogenic Cell Death, International Publications, Newcastle Disease Virus /von 2022-01-19 / Genes Immun 2022 02;23(1):1-11GP96 and SMP30 Protein Priming of Dendritic Cell Vaccination Induces a More Potent CTL Response against Hepatoma
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2022-01-07 / J Healthc Eng 2022;2022:2518847Cancer vaccines as a targeted immunotherapy approach for breast cancer: an update of clinical evidence
/in Breast Cancer, Dendritic Cells, International Publications /von 2022-01-06 / Expert Rev Vaccines 2022 Mar;21(3):337-353Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2022-01-01 / J Immunother Cancer 2022 Jan;10(1)A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients
/in Dendritic Cells, International Publications, NSCLC /von 2022-01-01 / Integr Cancer Ther 2022;21:15347354221083968
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution